Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: A randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU).

Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: A randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU).

<h4>Background</h4>After admission to hospital, COVID-19 progresses in a substantial proportion of patients to critical disease that requires intensive care unit (ICU) admission.<h4>Methods</h4>In a pragmatic, non-blinded trial, 387 patients aged 40-90 years were randomised t...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Raja Dhar, John Kirkpatrick, Laura Gilbert, Arjun Khanna, Mahavir Madhavdas Modi, Rakesh K Chawla, Sonia Dalal, Venkata Nagarjuna Maturu, Marcel Stern, Oliver T Keppler, Ratko Djukanovic, Stephan D Gadola
التنسيق: مقال
اللغة:English
منشور في: Public Library of Science (PLoS) 2023-01-01
سلاسل:PLoS ONE
الوصول للمادة أونلاين:https://doi.org/10.1371/journal.pone.0280745

مواد مشابهة

مواد مشابهة